March 20, 2020

COVID-19 Update

In response to the coronavirus (COVID-19), Affinity Biologicals is acting to ensure the continuity of our product manufacturing and distribution along with our service levels. Ensuring the well-being of our employees is an important part of our response plan. Currently, we do not anticipate any significant disruptions. We are committed to delivering the quality products and services our customers have come to expect from us.

We continue to closely monitor the unfolding situation and will post updates on our website as they become available.

FAQs

What is Affinity Biologicals’ risk mitigation plan for COVID-19?

Several actions have been taken thus far to mitigate the impact of COVID-19 including:

• Establishing a COVID-19 response team to monitor the unfolding situation and help ensure continuity of critical operations
• Maximizing inventory levels of raw materials and finished goods
• Working closely with suppliers to avoid or minimize supply chain disruptions
• Educating and supporting our employees to ensure their well-being

We are actively monitoring the situation and will adjust our plan accordingly.

Are you experiencing or do you anticipate any disruption or delay to supply?

Currently, we are not experiencing nor do we anticipate any significant disruptions to our supply of raw materials and our ability to supply finished goods. We are committed to helping our customers deliver timely, accurate test results.

What are you doing to protect your employees from COVID-19?

 Ensuring the well-being of our employees is an important part of our response plan. We have and will continue to identify risks in the workplace and implement proper controls to address those risks. Actions include:

• Educating and supporting our employees to ensure their well-being
• Supporting social distancing efforts by enabling as many employees as possible to work from home and implementing measures to protect those employees whose roles require them to work onsite
• Requesting employees stay home from the office for a period of 14 days (the incubation period of COVID-19), and/or until medically cleared to return to work, if they:
  • travelled outside of Canada recently
  • were near someone who was diagnosed with COVID-19 or who is suspected of having COVID-19 based on symptoms, travel or contact history; or
  • were diagnosed with or suspect they may have COVID-19 based on symptoms, travel or contact history.

We are committed to providing our products and service throughout this situation. Please visit our website www.affinitybiologicals.com for updates.

Thank you for your trust in Affinity Biologicals and our products.

Sincerely,

Paul Empey

President and CEO